Upload File

The top documents of roopal

Disclosure of Commission FY 13 14-Mutual Fund
Disclosure of Commission FY 13 14-Mutual Fund
225 views
Su2085 Association of Baseline C-Reactive Protein With Maintenance of Remission in Anti-TNF-Experienced Patients With Moderate to Severe Crohn's Disease Treated With Adalimumab
Su2085 Association of Baseline C-Reactive Protein With Maintenance of Remission in Anti-TNF-Experienced Patients With Moderate to Severe Crohn's Disease Treated With Adalimumab
218 views
Mo1219 Adalimumab Achieves Efficacy in Mucosal Healing Regardless of Baseline Disease Severity in Patients With Crohn's Disease: Data From EXTEND
Mo1219 Adalimumab Achieves Efficacy in Mucosal Healing Regardless of Baseline Disease Severity in Patients With Crohn's Disease: Data From EXTEND
219 views
Sa1152 Long-Term Safety of Adalimumab in Pediatric Patients With Crohn's Disease
Sa1152 Long-Term Safety of Adalimumab in Pediatric Patients With Crohn's Disease
212 views
Sa1204 Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Sa1204 Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
213 views
Mo1221 Adalimumab Maintains Remission for Up to 4 Years in Patients With Ulcerative Colitis
Mo1221 Adalimumab Maintains Remission for Up to 4 Years in Patients With Ulcerative Colitis
213 views
Sa1213 Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients
Sa1213 Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients
215 views
Sa1208 Sustained Efficacy in Patients With Ulcerative Colitis Treated With Adalimumab: Results From ULTRA 2
Sa1208 Sustained Efficacy in Patients With Ulcerative Colitis Treated With Adalimumab: Results From ULTRA 2
212 views
Mo1220 Patient-Reported Symptom Measures Differ in Their Association With Mucosal Healing in Adults With Moderately to Severely Active Ulcerative Colitis: Results From ULTRA 1 and
Mo1220 Patient-Reported Symptom Measures Differ in Their Association With Mucosal Healing in Adults With Moderately to Severely Active Ulcerative Colitis: Results From ULTRA 1 and
212 views
Su2078 Concomitant use of Adalimumab and Immunomodulators Compared With Adalimumab Alone: Pooled Malignancy Safety Analysis
Su2078 Concomitant use of Adalimumab and Immunomodulators Compared With Adalimumab Alone: Pooled Malignancy Safety Analysis
212 views
93 Rate of and Response to Dose Escalation in Pediatric Patients With Crohn's Disease From IMAgINE 1
93 Rate of and Response to Dose Escalation in Pediatric Patients With Crohn's Disease From IMAgINE 1
218 views
Sa1214 Rates of “Patient-Defined” Remission With Adalimumab in Patients With Ulcerative Colitis: Subanalysis of ULTRA 1 and ULTRA 2
Sa1214 Rates of “Patient-Defined” Remission With Adalimumab in Patients With Ulcerative Colitis: Subanalysis of ULTRA 1 and ULTRA 2
213 views
Mo1205 Evaluation of Site Versus Central Assessment of Endoscopies in Crohn's Disease: Comparison Using Data From EXTEND
Mo1205 Evaluation of Site Versus Central Assessment of Endoscopies in Crohn's Disease: Comparison Using Data From EXTEND
213 views
Su2083 One-Year Response and Remission Rates in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of Ultra 2
Su2083 One-Year Response and Remission Rates in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of Ultra 2
213 views
Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials
Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials
213 views
Sa1151 Steroid-Free Remission in Adalimumab-Treated Pediatric Patients With Moderately to Severely Active Crohn's Disease in the IMAgINE 1 Trial
Sa1151 Steroid-Free Remission in Adalimumab-Treated Pediatric Patients With Moderately to Severely Active Crohn's Disease in the IMAgINE 1 Trial
214 views